Gilead prepares for anticipated hep C drug approval with plant expansion

If the FDA takes the recommendation from a panel that voted 15-0 last week to approve hep C treatment sofosbuvir, maker Gilead ($GILD) will be ready. It's expanding the facility that will manufacture the drug--a Canadian plant in Edmonton, Alberta--with additions worth $47 million. That will cover 45,000 square feet of lab and research space, which will come along with 80 jobs, the company says. More